As funding from the Innovative Medicines Initiative ended at the close of the project, the project partners decided to sustain this work through a non-profit organisation. This is how VAC4EU was established. You can learn more about that following link below.
Impact
Aside from the establishment of VAC4EU as a follow up, ADVANCE had many outputs and many lessons to share with the world. We invite you to browse through these with the links aside!
Outputs
Throughout its duration, ADVANCE generated a wealth of knowledge and practical tools for vaccine benefit-risk assessment. Explore the project’s outputs below to discover its publications, deliverables, webinars, and other materials that continue to inform evidence-based vaccine monitoring today.
-
List of study needs and framework requirements draft R Month 61.01
-
List of topics for proof-of-concept studies Ph I R Month 61.02
-
Final report on existing models of public-private interactions R Month 91.03
-
Analysis of public concerns and perceptions related to benefits and risks of vaccines R Month 121.04
-
Initial conceptual model for public-private interaction R Month 151.05
-
Guidance on best practices draft P Month 181.06
-
Conference "EU ecosystem for monitoring of post-licensure vaccine benefit and risk: From ADVANCE to VAC4EU"6 March 2019
-
Interactive dashboard to monitor vaccine benefit and risk